Coinfar

COINFAR (Consórcio de Inovação Farmacêutica) was a pioneering Brazilian biotechnology consortium established to transform the country's vast biodiversity into innovative therapeutic products. Formed as a joint venture between prominent pharmaceutical companies Biolab-Sanus, Biosintética, and União Química, the entity functioned as a virtual biotech model, coordinating R&D efforts across a network of universities and research institutes like the Butantan Institute. The company's research focused primarily on oncology, chronic pain, and wound healing, utilizing natural products and venom-derived peptides as lead compounds. Notable pipeline candidates included Evasin, a novel anti-hypertensive agent, and CNF021.03, a peptide-based analgesic targeting opioid receptors. While the consortium was a landmark initiative in the Brazilian life sciences sector, its specific collaborative projects have largely transitioned into the independent pipelines of its founding partners.